Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$6.30 USD
-0.13 (-2.02%)
Updated Aug 6, 2025 12:48 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
COYA 6.30 -0.13(-2.02%)
Will COYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Other News for COYA
Coya Therapeutics (COYA) Maintains Buy Rating with Target Price of $18 | COYA Stock News
Coya Therapeutics (COYA) Research Sheds Light on PD Immune Dysfunction | COYA Stock News
Coya Therapeutics publishes new research study on progression of Parkinson's
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and ...
Sixteen new option listings on July 23rd